Young Sohn, who is now a senior adviser at Samsung, will create a new venture fund with Shankar Chandran and Francis Ho, former heads of Samsung’s Catalyst corporate venturing unit.
Month: March 2021
PrimeGov propels itself to Rock Solid acquisition
Rock Solid Technologies is purchasing the meeting management platform developer in a deal allowing Propylon to exit.
Linklogis links to public markets
The supply chain financing platform has filed to raise up to $1.06bn in a Hong Kong Stock Exchange offering which will enable Bertelsmann, GLP, Skyworth and Tencent to exit.
Zhihu sees its way to $523m IPO
The online question-and-answer platform developer is going public alongside a $250m private placement featuring JD.com, Alibaba, Tencent and Lilith Games.
Morphisec raises more in $31m round
Orange and Deutsche Telekom Capital Partners both chipped in as the cybersecurity software provider looks to ramp up hiring.
Ease onboards $41m in series C round
Propel Venture Partners returned to help the employee benefits platform developer hike its total funding to more than $70m.
Corporates move in as Digital House raises $50m
Globant and Mercado Libre both invested having partnered the coding education provider on a two-year programme about to launch.
Gorillas grabs $290m in series B
Tencent helped the grocery delivery service become the quickest European company ever to achieve a unicorn valuation.
Hopper jumps to $170m series F
Capital One has led a round that included Citi Ventures, increasing the ticket and hotel booking portal’s overall funding to $435m.
Zymergen zooms to IPO stage
Hanwha and SoftBank could exit the advanced biomaterials developer in the offering, which will follow more than $870m in funding.
Ginger snaps up $100m in series E
The Cigna and Kaiser Permanente-backed mental healthcare app developer took its total funding to $220m in a round valuing it at about $1bn.
PPRO propels latest round to $270m
The Paypal and Citi-backed payment platform developer has secured an additional $90m following a $180m close in January.
Gyroscope turns to Fosun for $148m round
Retinal disease drug developer Gyroscope Therapeutics has raised series C funding from investors including Fosun Pharma.
Noile-Immune negotiates series C funding
The solid tumour therapy developer secured $21.9m from investors including Dai-ichi Life, Binex, Bigen and Shibuya Kogyo.